Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30280973 | 0.90 | GPR119 (0.41) | GPR119ARIRAK4EGLN2USP30 | |
| SCHEMBL28974034 | 0.90 | GPR119 (0.43) | GPR119ARIRAK4EGLN2USP30 | |
| SCHEMBL30280675 | 0.86 | GPR119 (0.43) | GPR119ARIRAK4DPP4EGLN2 | |
| SCHEMBL30280984 | 0.84 | GPR119 (0.47) | GPR119ARIRAK4EGLN2 | |
| SCHEMBL30280956 | 0.77 | GPR119 (0.55) | GPR119IRAK4EGLN2USP30 | |
| SCHEMBL5468493 | 0.77 | GPR119 (0.55) | GPR119IRAK4EGLN2USP30 | |
| SCHEMBL30547518 | 0.77 | GPR119 (0.41) | GPR119IRAK4EGLN2USP30 | |
| SCHEMBL30339030 | 0.77 | GPR119 (0.41) | GPR119IRAK4EGLN2USP30 | |
| SCHEMBL29048236 | 0.77 | GPR119 (0.41) | GPR119IRAK4EGLN2USP30 | |
| SCHEMBL25816599 | 0.77 | GPR119 (0.41) | GPR119IRAK4EGLN2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116139138-A | Heterocyclic modulators of lipid synthesis | 3-V生物科学股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-110177551-B | Heterocyclic modulators of lipid synthesis | 3-V生物科学股份有限公司 | 2023-02-17 | — | — | CN | disclosed |